Injection Molding Microcellular Foaming Patents 2026
Injection Molding Microcellular Foaming Patents
Supercritical fluid-based microcellular foaming delivers weight reductions of 5–30% with cell structures below 100 µm. As Trexel’s foundational MuCell® IP enters the public domain, a new wave of material and tooling patents is reshaping the competitive landscape.
Microcellular Foaming: From MuCell® Foundations to Emerging Material Innovation
Injection molding microcellular foaming dissolves N₂ or CO₂ under supercritical conditions into a polymer melt to form a single-phase solution. A rapid pressure drop on injection nucleates millions of micro-scale cells that stabilize during cooling, producing parts with weight reductions of 5–30%, reduced warpage, and shortened cycle times versus conventional injection molding.
The technology is commercially anchored by Trexel’s MuCell® platform, with foundational patents filed from 1998 to 2004 across WO, EP, AU, CA, and US jurisdictions. With the majority of these early filings now showing inactive legal status, the core process architecture is substantially entering the public domain, lowering barriers for new entrants and redirecting competition toward differentiated materials and tooling.
Four core technical sub-domains structure activity in this dataset: SCF nucleation and process control, mold cavity dynamics including core-back and variable-volume tooling, surface quality improvement through gas counter-pressure and hybrid processes, and novel material systems spanning fiber-reinforced polyamides, PP nanocomposites, biodegradable biopolymers, and silicone-functionalized polyolefin blends.
In this dataset, Trexel, Inc. leads by filing volume with 15+ patent records, followed by DIAB International AB with 6+ active records across five jurisdictions. Chinese assignees Dongguan Hailex and Guizhou Material Industrial Technology Institute are executing active international prosecution strategies, with filings in US and ZA jurisdictions respectively, representing a notable shift in geographic origin among recent filers in retrieved records.
Filing Activity, Technology Clusters, and Jurisdictional Distribution
Analysis of retrieved patent and literature records reveals three distinct activity phases: foundational filings by Trexel (1998–2012), mid-stage tooling and material innovation (2008–2016), and a current wave of material diversification and process optimization (2019–2025).
Patent Filing Activity by Technology Cluster (Dataset Snapshot)
In this dataset, SCF nucleation systems represent the largest cluster by filing count, reflecting Trexel’s foundational multi-jurisdiction portfolio, while novel material systems show the most recent growth concentrated in 2019–2023 filings.
↗ Click bars to explorePatent Filing Activity by Era — Microcellular Foaming (Dataset Snapshot)
In this dataset, the 2019–2025 filing era shows the broadest assignee diversity with entries from Dow, IACGNA, Guizhou, and Hailex, contrasting with the 1997–2007 era dominated almost entirely by Trexel foundational filings.
↗ Click bars to exploreKey Application Domains for Microcellular Foaming Technology
Microcellular injection foaming has established commercial presence across automotive, footwear, consumer goods, and packaging sectors, with each domain presenting distinct material and process requirements documented across patent and literature records in this dataset.
Automotive Structural Components
The most consistently cited application domain across retrieved literature records, covering thick-walled PA66/GF30 parts, inlet air filters, cockpits, gearbox casings, and radiator baffles. Core-back foaming of PA6 achieves cell densities of 12.5 × 10⁵ cells/cm³, approximately 3.5× higher than short-shot foaming at 10% weight reduction. International Automotive Components Group NA filed a WO patent in 2025 for core-back foamed soft skin targeting vehicle interior surfaces.
LightweightingFootwear & Sporting Goods
MuCell® applied to thermoplastic polyurethane (TPU) midsoles is an active development area, with non-uniform cell size identified as the key technical barrier. O2 Partners LLC holds active US and AU patents (2019–2020) covering biodegradable microcellular foams specifically for footwear components, protective gear, and watersport accessories. Gas counter-pressure is applied to achieve cosmetically acceptable surfaces in these novel biodegradable material systems.
Sustainable FoamConsumer & Personal Care Products
Playtex Products LLC held an EP patent (2013, now inactive) for microcellular injection molding of feminine hygiene devices using supercritical fluid blending. The Procter & Gamble Company’s co-injection molding system (WO, 2013) targets sustainable consumer product components with embedded biodegradable materials including PLA and starch. This domain represents early-stage commercial deployment with core IP now largely lapsed.
Consumer GoodsPackaging & Industrial Components
Trexel’s microcellular extrusion/blow molding patent family (EP/WO/CA/AU, 1999–2012) targets thin-walled, non-liquid-permeable containers, extending the microcellular concept beyond injection molding. A 2014 lifecycle assessment study confirmed that a 16% weight reduction from microcellular foaming translated into measurable environmental impact reduction on an industrial component without loss of mechanical functionality. Home appliances are also cited as an established application domain across multiple literature records.
Industrial / PackagingKey Patent Assignees in Microcellular Foaming — Dataset Snapshot
In this dataset, Trexel, Inc. accounts for the largest filing volume with 15+ records spanning five jurisdictions from 1998 to 2012, while DIAB International AB holds the second-largest active family in retrieved records with 6+ filings across WO, CA, IN, EP, and US jurisdictions from 2015 to 2023.
Top Assignees by Filing Count — Microcellular Foaming (Dataset Snapshot)
↗ Click bars to exploreTrexel, Inc.
Trexel holds 15+ patent records in this dataset spanning WO, EP, AU, CA, and US jurisdictions from 1998 to 2012, covering SCF dissolution, pressure-drop nucleation, reciprocating screw integration, thin-wall capability, crystalline/semicrystalline material injection, and blow molding variants. The majority of these foundational MuCell® patents now show inactive legal status, indicating the core process architecture is entering the public domain. Filings include landmark records such as “Injection Molding of Microcellular Material” (1998, WO) and “Injection Molding of Polymeric Material” (2006/2012, US).
United StatesDIAB International AB
DIAB International AB holds 6+ active patent records in this dataset across WO, CA, IN, EP, and US jurisdictions from 2015 to 2023, centered on a variable-cavity-volume mold that prevents premature foaming and enables semi-foamed “embryo” production for downstream expansion. Most recent active filings are in India (IN, 2023) and Canada (CA, 2022), indicating ongoing global prosecution. The EP and US patents for “Apparatus and Method for the Production of Expanded Foam Embryos” (2016) are the anchor filings of this family.
SwedenFive Frontier Signals in Microcellular Foaming (2022–2025)
The most recent filings and literature records from 2022 to 2025 in this dataset point to five directional shifts: biodegradable foam systems, silicone-functionalized polyolefin blends, automotive soft-skin overmolding, process simulation maturation, and nanocellular/bimodal foam morphologies.
Biodegradable and Bio-Derived Microcellular Foams
O2 Partners LLC holds active US and AU patents (2019–2020) for industrially compostable microcellular flexible foams targeting footwear, protective gear, and watersport accessories. Academic research on PMMA/PVDF CO₂ foaming (2023) signals continued development of compostable and biopolymer-based systems. Gas counter-pressure is applied in these novel material systems to achieve cosmetically acceptable surfaces.
Nanocellular and Bimodal Foam Morphologies
A 2020 literature study demonstrates bimodal nanoporous PP/talc composite foams produced via fast-cooling microcellular injection molding, achieving toughness 327% higher than conventional microcellular foams. This frontier direction combines nanocellular and microcellular structures through rapid cooling design. The approach represents a performance step-change without requiring expensive fiber reinforcement modifiers.
MuCell® (Trexel) vs. Ku-Fizz™ — Microcellular Foaming Platform Comparison
Click any row to explore further.
| Dimension | MuCell® (Trexel) | Ku-Fizz™ |
|---|---|---|
| Blowing Agent | Supercritical N₂ or CO₂ injected under controlled pressure | Lower-pressure gas-dosing approach (inert gas) |
| Cell Size | Typically below 100 µm; PA6 core-back achieves ~30 µm | Cell microstructure affected by gas pressure; documented in 2021 literature |
| Primary Target Material | Broad polymer range: PA, PP, TPU, LDPE, semicrystalline polymers | Glass-fiber-reinforced PP compounds for automotive structural components |
| Application Focus | Automotive, footwear, consumer goods, packaging — thousands of applications globally cited | Automotive structural components; emerging platform |
| IP Status | Foundational patents (1998–2004) majority inactive; core process in public domain | Emerging alternative; no patent records captured in this dataset |
| Process Maturity | Commercially mature; deployed in thousands of automotive applications globally | Alternative lower-pressure platform; research-stage documentation as of 2021 |
| Surface Quality Challenge | Silver flow marks; addressed via GCP, core-back, RHCM, and IMD hybrid methods | Gas pressure effect on microstructure documented; surface quality data limited in dataset |
Frequently Asked Questions: Injection Molding Microcellular Foaming
According to records in this dataset, microcellular injection foaming delivers weight reductions of 5–30% relative to conventional injection molding, while also reducing warpage, sink marks, and cycle times.
Cell structures are typically below 100 µm in diameter. Core-back foaming of fiber-reinforced polyamide (PA66/GF30) can achieve cell diameters of approximately 30 µm, while silicone-functionalized LDPE blends achieve cell sizes below 60 µm according to Dow’s 2022/2023 filings.
The majority of Trexel’s foundational MuCell® patents filed between 1998 and 2004 now show inactive legal status across EP, US, AU, CA, and WO jurisdictions, meaning the core process architecture is substantially entering or has entered the public domain, lowering barriers for third-party implementation.
Silver flow marks and surface gloss degradation are identified in this dataset as the primary barrier to wider adoption across all recent literature and process patents. IP strategies combining gas counter-pressure (GCP), core-back tooling, in-mold decoration, and dynamic thermal control are the leading approaches to address this challenge.
Based on filings from 2019–2025 in this dataset, the leading emerging material systems are: biodegradable biopolymer foams (O2 Partners, US/AU), silicone-functionalized LDPE blends achieving sub-60 µm cells (Dow Global Technologies, WO/US), and bimodal nanoporous PP/talc composites demonstrating 327% higher toughness than conventional microcellular foams.
Automotive remains the highest-volume commercial application domain in this dataset, with active filings from DIAB International AB, International Automotive Components Group NA (WO, 2025), and sustained literature on PA66/GF30 thick-wall components. Footwear and sustainable consumer goods are the fastest-growing emerging application sectors based on 2019–2025 filings.
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.